Results Transparency Scoreboard

EU Clinical Trials Regulation 536/2014, Article 37(4): summary of results due within 12 months from end of trial in all Member States concerned (6 months for paediatric trials).

3,459 ended trials 1,008 results posted 854 overdue 1,597 in grace period 29.1% global compliance

As of 7 July 2026 · CTIS public registry snapshot · 2,169 trials excluded (no end date reported)

3,459 Ended trials
incl. 346 paediatric
1,008 Results posted
854 Overdue
past 12m (6m paediatric)
1,597 In grace period
deadline not yet elapsed
29.1% Global compliance

Compliance by year of trial end (2021 onwards):

2022: 83.3% (6) 2023: 84.2% (133) 2024: 42.8% (671) 2025: 32.3% (1,792) 2026: 3% (856)

Recent years (2025–2026) include trials still within the 12-month grace period (6 months for paediatric) — those are not counted as overdue. Years 2020 and earlier are excluded: they fall under Directive 2001/20/EC / Commission Guidelines 2012/C 302/03 and are tracked in EudraCT/EUCTR, not CTIS.

Regulatory context

Under Article 37(4) of Regulation (EU) No 536/2014, sponsors must submit a summary of clinical trial results to the EU database within 12 months of the end of the trial in all Member States concerned (6 months for paediatric trials), unless scientific reasons justifying delay are pre-specified in the protocol.

This scoreboard tracks compliance based on publicly available CTIS data for trials authorised under CTR (post-31 January 2022). Legacy trials under Directive 2001/20/EC and the 2012 Commission Guidelines are tracked separately via EudraCT/EUCTR.

How we calculate these numbers (sponsor scoreboard methodology)

Population

  • Status: trials with ctPublicStatusCode IN ('5', '8') — i.e. "Ended" (5) or "Ended early/Halted-final" (8). Active, suspended, halted-pending and pre-approval statuses are excluded.
  • End date required: trials without endDateEU are excluded from the entire scoreboard (2,169 trials affected). Without a verified end date, Article 37(4) deadline cannot be evaluated.
  • Sponsor attribution: each trial is attributed to its primary sponsor (trial_sponsors.is_primary = 1). A small subset of trials (~167) declares two or more co-primary sponsors — those trials are attributed to each co-sponsor (every co-primary takes responsibility for results).
  • Sponsor deduplication: legal-form variants of the same organisation ("Novartis Pharma AG / GmbH / SAS") are collapsed via the canonical_sponsor_map table into a single row.
  • Visibility filter: only sponsors with ≥ 2 ended trials are shown (singletons are excluded — too few data points for a meaningful compliance rate).

Bucket definitions

  • Ended trials — distinct count of qualifying trials per sponsor (COUNT DISTINCT trial_id).
  • Results posted — trials where trial_results.summaryResults is non-null / non-empty (Annex IV summary submitted).
  • Layperson summary — same field check on trial_results.laypersonResults (Annex V).
  • Overdue — past the Article 37(4) deadline without posted results. Deadline = endDateEU + 12 months for adult trials, + 6 months for paediatric trials. Paediatric is determined from trial_details_information.ageRanges containing "1" (in utero) or "2" (0–17 years).
  • In grace period — ended on or before today, but deadline has not yet elapsed. Not counted as non-compliant.
  • Compliance % — results_posted / ended × 100, rounded to one decimal place.

Sponsor type

Academic vs. Commercial is a heuristic on the organisation name, not a CTIS field. A sponsor is tagged Academic if its name matches: University, Universit[eéà], Hospital, H[oô]pital, Institut, Foundation, Fondation, NHS, Academic, Research Centre, Centro, Klinik, Assistance, Charit[eé], APHP. Otherwise tagged Commercial. Edge cases (e.g. consortia, government bodies) may be misclassified.

Known caveats

  • The scientific-justification exception under Art. 37(4) is not exposed in public CTIS fields. Sponsors invoking it for legitimate scientific reasons will appear here as overdue. This is a known limitation of any CTIS-only audit.
  • Sums across sponsor rows can exceed the global totals because trials with co-primary sponsors are counted under each. The 5-tile global stats use COUNT DISTINCT trial_id and therefore count each trial exactly once.
  • This scoreboard only covers trials in CTIS (CTR-authorised, post-31 January 2022; fully migrated 31 January 2025). Pre-CTR trials reporting under Directive 2001/20/EC and the 2012 Commission Guidelines are tracked separately in EudraCT/EUCTR.
Sort by
# Sponsor Type Ended trials Results posted Layperson summary Compliance Overdue In grace
1 Merck Sharp & Dohme LLC Commercial 129 36 36
27.9%
34 60
2 Boehringer Ingelheim International GmbH Commercial 99 21 21
21.2%
45 35
3 AstraZeneca AB Commercial 78 18 19
23.1%
22 39
4 F. Hoffmann-La Roche AG Commercial 71 24 22
33.8%
21 30
5 Pfizer Inc. Commercial 63 15 15
23.8%
27 22
6 Janssen - Cilag International Commercial 57 15 14
26.3%
21 21
7 Novartis Pharma AG Commercial 57 21 20
36.8%
11 25
8 Novo Nordisk A/S Commercial 47 13 13
27.7%
10 24
9 AbbVie Deutschland GmbH & Co. KG Commercial 36 16 17
44.4%
4 17
10 Bayer AG Commercial 36 12 12
33.3%
13 13
11 Sanofi-Aventis Recherche & Developpement Commercial 36 10 10
27.8%
13 14
12 Eli Lilly & Co. Commercial 35 11 11
31.4%
5 20
13 Assistance Publique Hopitaux De Paris Academic 32 2 0
6.3%
9 22
14 Glaxosmithkline Research & Development Limited Commercial 31 11 11
35.5%
7 13
15 Sun Pharmaceutical Industries Limited Commercial 30 3 3
10%
12 15
16 Bristol Myers Squibb International Corporation Commercial 28 20 19
71.4%
4 6
17 Takeda Development Center Americas Inc. Commercial 26 13 13
50%
2 11
18 Centre Hospitalier Universitaire De Nantes Academic 25 5 5
20%
10 12
19 Laboratorios Normon S.A. Commercial 25 9 9
36%
9 7
20 Incyte Corp. Commercial 23 6 6
26.1%
2 15
21 Amgen Inc. Commercial 22 9 7
40.9%
3 10
22 Celgene Corp. Commercial 21 6 5
28.6%
13 5
23 Genentech Inc. Commercial 20 3 5
15%
4 13
24 Regeneron Pharmaceuticals Inc. Commercial 20 8 8
40%
3 9
25 Amsterdam UMC Stichting Commercial 19 4 3
21.1%
5 10
26 UZ Leuven Commercial 19 4 5
21.1%
1 14
27 CCDRD Cooperative Clinical Drug Research and Development AG Commercial 18 3 3
16.7%
8 7
28 Rigshospitalet Academic 18 2 2
11.1%
7 10
29 Bluepharma Industria Farmaceutica S.A. Commercial 17 4 4
23.5%
9 4
30 Chiesi Farmaceutici S.p.A. Commercial 17 3 3
17.6%
8 7
31 GlaxoSmithKline Biologicals Commercial 16 11 11
68.8%
1 6
32 Bristol-Myers Squibb Services Unlimited Company Commercial 15 3 3
20%
4 9
33 Laboratorios Cinfa S.A. Commercial 14 2 2
14.3%
4 8
34 Oslo University Hospital HF Academic 14 6 4
42.9%
1 8
35 UCB Biopharma Commercial 14 5 5
35.7%
1 8
36 Genmab A/S Commercial 13 7 7
53.8%
— 7
37 Laboratorios Alter S.A. Commercial 13 3 3
23.1%
6 4
38 Merck Healthcare KGaA Commercial 13 4 4
30.8%
5 4
39 Universitair Medisch Centrum Groningen Commercial 13 1 1
7.7%
4 8
40 Argenx Commercial 12 3 3
25%
1 8
41 Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) Commercial 12 1 1
8.3%
4 7
42 Gilead Sciences Inc. Commercial 12 6 6
50%
2 5
43 Institut De Recherches Internationales Servier IRIS Academic 12 2 2
16.7%
6 5
44 Adamed Pharma S.A. Commercial 11 2 2
18.2%
5 4
45 Bioprojet Pharma Commercial 11 4 4
36.4%
5 3
46 Laboratorios Leon Farma S.A. Commercial 11 2 2
18.2%
5 4
47 Seagen Inc. Commercial 11 2 2
18.2%
2 7
48 Universitair Medisch Centrum Utrecht Commercial 11 3 2
27.3%
2 6
49 Alexion Pharmaceuticals Inc. Commercial 10 4 4
40%
2 4
50 Daiichi Sankyo Inc. Commercial 10 1 1
10%
— 9
51 Medical University Of Vienna Academic 10 5 4
50%
— 5
52 Radboud universitair medisch centrum Stichting Commercial 10 1 1
10%
4 5
53 Universitaetsklinikum Heidelberg AöR Academic 10 2 2
20%
2 6
54 Bayer Consumer Care AG Commercial 9 5 5
55.6%
3 2
55 Centre for Human Drug Research Commercial 9 0 0
0%
6 3
56 CSL Behring LLC Commercial 9 5 5
55.6%
1 3
57 Farmalider S.A. Commercial 9 1 1
11.1%
4 4
58 Institut Gustave Roussy Academic 9 2 0
22.2%
6 3
59 Medica Scientia Innovation Research S.L. Commercial 9 5 5
55.6%
— 4
60 Odense University Hospital Academic 9 1 1
11.1%
— 8
61 Taiho Oncology Inc. Commercial 9 3 3
33.3%
3 3
62 Charite Universitaetsmedizin Berlin KöR Academic 8 3 3
37.5%
1 4
63 Hospices Civils De Lyon Commercial 8 0 0
0%
4 4
64 Kite Pharma Inc. Commercial 8 5 5
62.5%
2 1
65 Leids Universitair Medisch Centrum (LUMC) Commercial 8 1 1
12.5%
— 7
66 Region Midtjylland Commercial 8 2 2
25%
— 6
67 Amsterdam UMC Commercial 7 1 1
14.3%
1 5
68 Astellas Pharma Global Development Inc. Commercial 7 4 4
57.1%
1 2
69 Centre Leon Berard Commercial 7 1 1
14.3%
1 6
70 Dr. Falk Pharma GmbH Commercial 7 0 0
0%
4 3
71 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Academic 7 3 3
42.9%
— 4
72 Immunovant Sciences GmbH Commercial 7 0 0
0%
— 7
73 Ipsen Pharma Commercial 7 3 2
42.9%
3 1
74 Medical University Of Graz Academic 7 2 2
28.6%
— 5
75 Moderna Inc. Commercial 7 3 2
42.9%
4 —
76 Stichting Radboud University Medical Center Academic 7 2 2
28.6%
2 3
77 Tarchominskie Zaklady Farmaceutyczne Polfa S.A. Commercial 7 1 1
14.3%
1 5
78 Zealand Pharma A/S Commercial 7 1 1
14.3%
1 5
79 Aarhus Universitet Academic 6 3 4
50%
— 3
80 Abivax Commercial 6 2 0
33.3%
3 1
81 Antibiotice S.A. Commercial 6 1 0
16.7%
5 —
82 Arrowhead Pharmaceuticals Inc. Commercial 6 2 2
33.3%
— 4
83 Beigene Ltd. Commercial 6 3 3
50%
— 3
84 Faes Farma S.A. Commercial 6 0 0
0%
3 3
85 Fondation Franc.Cancerologie Digestive Academic 6 4 4
66.7%
— 2
86 Horizon Therapeutics Ireland Designated Activity Company Commercial 6 5 3
83.3%
— 1
87 Inmunotek S.L. Commercial 6 5 5
83.3%
— 1
88 Ionis Pharmaceuticals Inc. Commercial 6 2 2
33.3%
1 3
89 Karolinska University Hospital Academic 6 2 2
33.3%
2 2
90 Leiden University Medical Center Academic 6 4 3
66.7%
1 1
91 Medical University Of Gdansk Academic 6 1 1
16.7%
— 5
92 Ospedale San Raffaele S.r.l. Commercial 6 1 1
16.7%
1 4
93 Otsuka Pharmaceutical Development & Commercialization Inc. Commercial 6 4 4
66.7%
— 3
94 Pharming Technologies B.V. Commercial 6 1 1
16.7%
2 3
95 Pharvaris Netherlands B.V. Commercial 6 2 2
33.3%
4 —
96 Region Hovedstaden Commercial 6 2 1
33.3%
— 4
97 Region Skane Commercial 6 1 1
16.7%
1 4
98 Solti Group Commercial 6 3 3
50%
1 2
99 Tecnimede-Sociedade Tecnico-Medicinal S.A. Commercial 6 1 1
16.7%
3 2
100 Teikoku Seiyaku Co. Ltd. Commercial 6 1 1
16.7%
2 3
101 Teva Branded Pharmaceutical Products R&D LLC Commercial 6 2 2
33.3%
2 2
102 Academisch Ziekenhuis Leiden Commercial 5 1 1
20%
1 3
103 Antwerp University Hospital Academic 5 1 1
20%
2 2
104 BeOne Medicines AG Commercial 5 0 0
0%
— 5
105 Biogen Idec Research Limited Commercial 5 2 2
40%
— 3
106 BioNTech SE Commercial 5 0 0
0%
1 4
107 Centre hospitalier universitaire de Liege Academic 5 1 1
20%
— 4
108 Centre Hospitalier Universitaire De Saint Etienne Academic 5 0 0
0%
1 4
109 Chemo Research S.L. Commercial 5 2 2
40%
— 3
110 Crinetics Pharmaceuticals Inc. Commercial 5 0 0
0%
1 4
111 Dompe' Farmaceutici S.p.A. Commercial 5 5 5
100%
— —
112 Fundacio De Recerca Clinic Barcelona-Institut D’Investigacio… Academic 5 0 0
0%
1 4
113 Gentofte Hospital Academic 5 1 1
20%
— 5
114 H. Lundbeck A/S Commercial 5 2 2
40%
1 2
115 Insmed Inc. Commercial 5 1 1
20%
— 4
116 Institut Bergonie Academic 5 2 2
40%
— 4
117 Institut Curie Academic 5 4 3
80%
— 2
118 Intercept Pharmaceuticals Inc. Commercial 5 2 2
40%
— 3
119 Klinikum der Universitaet Muenchen AöR Academic 5 1 1
20%
— 4
120 Laboratorios Lesvi S.L. Commercial 5 4 4
80%
— 1
121 Leo Pharma A/S Commercial 5 1 1
20%
— 4
122 MoonLake Immunotherapeutics AG Commercial 5 0 0
0%
1 4
123 Myokardia Inc. Commercial 5 4 4
80%
1 1
124 Orion Corporation Commercial 5 2 2
40%
— 3
125 Pharma Mar S.A. Commercial 5 1 1
20%
— 4
126 PTC Therapeutics Inc. Commercial 5 3 3
60%
2 —
127 Sanofi-Aventis Research & Development Commercial 5 1 1
20%
2 2
128 Swedish Orphan Biovitrum AB (publ) Commercial 5 3 3
60%
— 2
129 Universitaetsklinikum Tuebingen AöR Academic 5 1 1
20%
— 4
130 University Medical Center Hamburg-Eppendorf Academic 5 1 1
20%
— 4
131 Vaestra Goetalandsregionen Commercial 5 2 2
40%
2 2
132 Vertex Pharmaceuticals Inc. Commercial 5 3 3
60%
— 2
133 Viiv Healthcare UK Limited Commercial 5 4 4
80%
— 2
134 Aalborg University Hospital Academic 4 1 1
25%
— 3
135 Agomab Spain S.L. Commercial 4 1 1
25%
1 2
136 Alx Oncology Inc. Commercial 4 1 1
25%
— 3
137 Arvinas Operations Inc. Commercial 4 0 0
0%
2 2
138 Bial Portela & Ca S.A. Commercial 4 0 0
0%
3 1
139 Biohaven Therapeutics Ltd. Commercial 4 1 1
25%
1 2
140 Cannaxan GmbH Commercial 4 0 0
0%
— 4
141 Celon Pharma S.A. Commercial 4 0 0
0%
3 1
142 Centre Hospitalier Regional Et Universitaire De Brest Academic 4 0 0
0%
— 4
143 Cepha s.r.o. Commercial 4 0 0
0%
4 —
144 Ferring Pharmaceuticals A/S Commercial 4 1 1
25%
1 2
145 Fundacion Publica Andaluza Para La Gestion De La Investigaci… Commercial 4 2 2
50%
— 2
146 Galapagos Commercial 4 1 1
25%
1 2
147 GE Healthcare Limited Commercial 4 0 0
0%
2 2
148 Genzyme Corp. Commercial 4 1 1
25%
1 2
149 Groupe Oncologie Radiotherapie Tete Cou Commercial 4 1 1
25%
1 2
150 Hipra Scientific S.L. Commercial 4 4 4
100%
— 1
151 HUS-Yhtymae Commercial 4 0 0
0%
2 2
152 Hutchmed Ltd. Commercial 4 0 0
0%
4 —
153 Idorsia Pharmaceuticals Ltd. Commercial 4 2 2
50%
1 2
154 Institute Of Tropical Medicine Academic 4 2 2
50%
2 1
155 Iovance Biotherapeutics Inc. Commercial 4 1 1
25%
— 3
156 Masarykova Univerzita Commercial 4 0 0
0%
2 2
157 Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Pan… Commercial 4 1 1
25%
2 2
158 Neurocrine Biosciences Inc. Commercial 4 2 2
50%
1 1
159 Parc De Salut Mar Commercial 4 0 0
0%
3 1
160 Pharmaplot P.C. Commercial 4 0 0
0%
4 —
161 Philogen S.p.A. Commercial 4 0 0
0%
1 3
162 Praxis Precision Medicines Inc. Commercial 4 1 1
25%
1 2
163 Prelude Therapeutics Inc. Commercial 4 0 0
0%
— 4
164 Quralis Corp. Commercial 4 0 0
0%
3 1
165 Region Uppsala Commercial 4 1 1
25%
1 2
166 Replimune Group Inc. Commercial 4 0 0
0%
— 4
167 ROXALL Medizin GmbH Commercial 4 0 0
0%
3 2
168 Sparrow Pharmaceuticals Inc. Commercial 4 0 0
0%
4 1
169 Technische Universitat Dresden Commercial 4 2 2
50%
— 2
170 Universitair Ziekenhuis Gent Commercial 4 1 1
25%
— 3
171 University College Dublin Academic 4 3 3
75%
1 —
172 Vianex S.A. Commercial 4 0 0
0%
1 3
173 Viridian Therapeutics Inc. Commercial 4 2 2
50%
— 2
174 Zaklady Farmaceutyczne Polpharma S.A. Commercial 4 0 0
0%
2 2
175 Aarhus University Hospital Academic 3 2 2
66.7%
— 1
176 Ab Science Commercial 3 0 0
0%
— 3
177 Acadia Pharmaceuticals Inc. Commercial 3 3 3
100%
— —
178 Acceleron Pharma Inc. Commercial 3 2 2
66.7%
— 1
179 Acelyrin Inc. Commercial 3 3 3
100%
— —
180 Achieve Life Sciences Inc. Commercial 3 3 3
100%
— —
181 Actelion Pharmaceuticals Ltd. Commercial 3 1 1
33.3%
1 1
182 ADC Therapeutics S.A. Commercial 3 1 1
33.3%
2 —
183 Alector LLC Commercial 3 3 3
100%
— —
184 Alfasigma S.p.A. Commercial 3 1 1
33.3%
1 1
185 Almirall S.A. Commercial 3 2 2
66.7%
— 1
186 Alnylam Pharmaceuticals Inc. Commercial 3 1 1
33.3%
1 3
187 Anaptysbio Inc. Commercial 3 1 1
33.3%
2 1
188 Apellis Pharmaceuticals Inc. Commercial 3 1 1
33.3%
1 1
189 Arcus Biosciences Inc. Commercial 3 0 0
0%
2 1
190 Areteia Therapeutics Inc. Commercial 3 0 0
0%
2 1
191 Bellvitge University Hospital Academic 3 0 0
0%
— 3
192 Blueprint Medicines Corp. Commercial 3 3 3
100%
— —
193 Cancer Trials Ireland Commercial 3 0 0
0%
— 3
194 Cardurion Pharmaceuticals Inc. Commercial 3 1 1
33.3%
— 2
195 Centre Hospitalier Regional Universitaire De Tours Academic 3 2 2
66.7%
— 1
196 Centre Hospitalier Universitaire De Bordeaux Academic 3 0 0
0%
1 2
197 Centre Hospitalier Universitaire Grenoble Alpes Academic 3 0 0
0%
3 —
198 Centre Hospitalier Universitaire Rouen Academic 3 0 0
0%
3 1
199 CHRU De Nancy Commercial 3 1 1
33.3%
— 2
200 Clinuvel Europe Limited Commercial 3 3 3
100%
— —
201 Curateq Biologics Private Limited Commercial 3 0 0
0%
— 3
202 Debiopharm International S.A. Commercial 3 0 0
0%
— 3
203 Deciphera Pharmaceuticals Inc. Commercial 3 0 0
0%
— 3
204 Dermax Commercial 3 1 1
33.3%
2 —
205 DICE Therapeutics Inc. Commercial 3 2 2
66.7%
— 1
206 Dragonfly Therapeutics Inc. Commercial 3 0 0
0%
— 3
207 Eurofins Optimed Commercial 3 0 0
0%
2 1
208 Fondation A De Rothschild Academic 3 1 1
33.3%
— 2
209 Fondazione Policlinico Universitario Agostino Gemelli IRCCS Commercial 3 1 1
33.3%
— 2
210 Fulcrum Therapeutics Inc. Commercial 3 3 3
100%
— —
211 Fundacion Grupo Espanol De Investigacion En Cancer De Mama Commercial 3 1 1
33.3%
— 2
212 Fundacion Seimc Gesida Commercial 3 1 2
33.3%
1 2
213 Goethe University Frankfurt Academic 3 1 1
33.3%
— 2
214 H e x a l AG Commercial 3 0 0
0%
— 3
215 Hansa Biopharma AB Commercial 3 1 1
33.3%
— 2
216 Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichtin… Commercial 3 0 0
0%
— 3
217 Herlev Hospital Academic 3 3 3
100%
— —
218 Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Zieke… Commercial 3 0 0
0%
— 3
219 Hifibio Inc. Commercial 3 0 0
0%
— 3
220 Hospital General Universitario Dr. Balmis Academic 3 2 0
66.7%
1 —
221 IGM Biosciences Inc. Commercial 3 0 0
0%
3 —
222 InflaRx GmbH Commercial 3 1 1
33.3%
1 1
223 Institut De Cancerologie De L Ouest Academic 3 0 0
0%
— 3
224 Instytut Pomnik Centrum Zdrowia Dziecka Commercial 3 0 0
0%
3 —
225 IO Biotech ApS Commercial 3 1 1
33.3%
— 2
226 Istituto Di Ricerche Farmacologiche Mario Negri Commercial 3 1 1
33.3%
— 2
227 iTeos Belgium Commercial 3 2 2
66.7%
— 1
228 K-Group Beta Inc. Commercial 3 1 1
33.3%
— 2
229 Kowa Research Institute Inc. Academic 3 0 0
0%
— 3
230 KRKA tovarna zdravil d.d. Novo mesto Commercial 3 2 2
66.7%
— 1
231 Les Hopitaux Universitaires De Strasbourg Commercial 3 0 0
0%
2 1
232 Martin-Luther-Universitaet Halle-Wittenberg Commercial 3 2 2
66.7%
— 1
233 Medical University Of Warsaw Academic 3 0 0
0%
1 2
234 Noucor Health S.A. Commercial 3 0 0
0%
1 2
235 Novadip Biosciences Commercial 3 0 0
0%
1 2
236 Octapharma Pharmazeutika Produktionsgesellschaft mbH Commercial 3 1 1
33.3%
1 1
237 Oncopole Claudius Regaud Commercial 3 2 1
66.7%
— 1
238 Royal College Of Surgeons In Ireland Commercial 3 2 2
66.7%
— 1
239 Sage Therapeutics Inc. Commercial 3 1 1
33.3%
1 1
240 Sarepta Therapeutics Inc. Commercial 3 2 2
66.7%
1 —
241 Sk Life Science Inc. Commercial 3 2 2
66.7%
— 1
242 Sutro Biopharma Inc. Commercial 3 0 0
0%
2 1
243 Syros Pharmaceuticals Inc. Commercial 3 0 0
0%
3 —
244 TargED Biopharmaceuticals B.V. Commercial 3 1 1
33.3%
1 1
245 Unicancer Commercial 3 0 0
0%
2 1
246 Universitaet Muenster Commercial 3 1 1
33.3%
1 1
247 Universitaetsklinikum Essen AöR Academic 3 0 0
0%
— 3
248 Universitaetsklinikum Schleswig-Holstein AöR Academic 3 0 0
0%
— 3
249 Universitaetsmedizin Goettingen Commercial 3 0 0
0%
— 3
250 University Hospital Maastricht Academic 3 3 3
100%
— —
251 University Medical Center Utrecht Academic 3 2 2
66.7%
— 1
252 University Of Cologne Academic 3 3 3
100%
— —
253 University Of Minnesota Academic 3 2 2
66.7%
— 1
254 Abcuro Inc. Commercial 2 0 0
0%
— 2
255 Achilles Therapeutics UK Limited Commercial 2 2 2
100%
— —
256 Aco Hud Nordic AB Commercial 2 1 1
50%
1 —
257 Aerovate Therapeutics Inc. Commercial 2 2 2
100%
— —
258 Affimed GmbH Commercial 2 0 2
0%
4 —
259 AiCuris Anti-infective Cures AG Commercial 2 0 0
0%
1 1
260 Akamis Bio Limited Commercial 2 0 0
0%
2 —
261 Alentis Therapeutics AG Commercial 2 1 1
50%
1 —
262 Alkaloid AD Skopje Commercial 2 0 0
0%
2 —
263 Alkermes Inc. Commercial 2 0 0
0%
— 2
264 Allogene Therapeutics Inc. Commercial 2 1 1
50%
1 —
265 Alter Farmacia S.A. Commercial 2 1 1
50%
1 —
266 Alumis Inc. Commercial 2 0 0
0%
— 2
267 Alvotech Swiss AG Commercial 2 1 1
50%
— 1
268 AM-Pharma B.V. Commercial 2 2 2
100%
— —
269 Amylyx Pharmaceuticals EMEA B.V. Commercial 2 0 0
0%
2 —
270 Amylyx Pharmaceuticals Inc. Commercial 2 1 1
50%
1 —
271 Amzell B.V. Commercial 2 1 1
50%
1 —
272 Anthos Therapeutics Inc. Commercial 2 0 0
0%
— 2
273 Apcintex Limited Commercial 2 2 2
100%
— —
274 Arbutus Biopharma Inc. Commercial 2 0 0
0%
1 1
275 Ascendis Pharma Oncology Division A/S Commercial 2 1 1
50%
— 1
276 Association International Extranodal Lymphoma Study Group (I… Commercial 2 0 0
0%
— 2
277 Atea Pharmaceuticals Inc. Commercial 2 3 3
150%
— —
278 Azafaros B.V. Commercial 2 1 1
50%
1 —
279 Baxalta Innovations GmbH Commercial 2 0 0
0%
1 1
280 Bial R&D Investments S.A. Commercial 2 0 0
0%
— 2
281 Biocodex Commercial 2 0 0
0%
1 1
282 BioInvent International AB Commercial 2 0 0
0%
— 2
283 Biomarin Pharmaceutical Inc. Commercial 2 0 0
0%
1 1
284 Bispebjerg Hospital Academic 2 0 0
0%
1 1
285 Bolt Biotherapeutics Inc. Commercial 2 2 2
100%
— —
286 Breye Therapeutics ApS Commercial 2 0 0
0%
1 1
287 Calliditas Therapeutics Suisse S.A. Commercial 2 2 2
100%
— —
288 Camurus AB Commercial 2 1 1
50%
— 1
289 Cardiol Therapeutics Inc. Commercial 2 1 1
50%
1 —
290 Carrick Therapeutics Limited Commercial 2 0 0
0%
— 2
291 Cassiopea S.p.A. Commercial 2 0 0
0%
1 2
292 Celgene International II SARL Commercial 2 2 2
100%
— —
293 Cell2cure ApS Commercial 2 0 0
0%
— 2
294 Cellaïon SA Commercial 2 2 2
100%
— —
295 Celldex Therapeutics Inc. Commercial 2 0 0
0%
— 2
296 Celltrion Inc. Commercial 2 0 0
0%
— 2
297 Centre Francois Baclesse Commercial 2 2 2
100%
— —
298 Centre Hospitalier Departemental Vendee Academic 2 1 1
50%
— 1
299 Centre Hospitalier Regional De Marseille Academic 2 0 0
0%
1 1
300 Centre Hospitalier Universitaire Amiens Picardie Academic 2 0 0
0%
1 1
301 Centre Hospitalier Universitaire D'Angers Academic 2 0 0
0%
— 2
302 Centre Hospitalier Universitaire De Dijon Academic 2 0 0
0%
2 —
303 Cerevel Therapeutics LLC Commercial 2 1 1
50%
— 1
304 CHU Gabriel-Montpied Commercial 2 0 0
0%
— 2
305 Cinclus Pharma Holding AB (publ) Commercial 2 0 0
0%
— 2
306 Clinica Universidad De Navarra Commercial 2 1 1
50%
— 1
307 Cliniques Universitaires Saint-Luc Commercial 2 1 1
50%
1 —
308 Consorcio Centro De Investigacion Biomedica En Red Academic 2 1 1
50%
— 1
309 Cr2o B.V. Commercial 2 1 1
50%
1 —
310 Curevac AG Commercial 2 0 0
0%
— 2
311 Curis Inc. Commercial 2 0 0
0%
2 —
312 Cyclacel Limited Commercial 2 0 0
0%
2 —
313 Cytokinetics Inc. Commercial 2 1 1
50%
— 1
314 Delix Therapeutics Inc. Commercial 2 0 0
0%
3 —
315 Dermapharm AG Commercial 2 0 0
0%
— 2
316 Diamyd Medical AB Commercial 2 0 0
0%
— 2
317 Diater Laboratorio De Diagnostico Y Aplicaciones Terapeutica… Commercial 2 2 2
100%
— —
318 Dicot AB Commercial 2 1 1
50%
2 —
319 Direction Centrale Du Service De Sante Des Armees Commercial 2 0 0
0%
2 —
320 Dr. Willmar Schwabe GmbH & Co. KG Commercial 2 1 1
50%
1 —
321 Eip Pharma Inc. Commercial 2 0 0
0%
1 1
322 Eisai Limited Commercial 2 1 1
50%
1 —
323 Empros Pharma AB Commercial 2 2 2
100%
— —
324 ENYO Pharma Commercial 2 0 0
0%
— 2
325 Epiendo Pharmaceuticals ehf. Commercial 2 0 0
0%
2 1
326 Epizyme Inc. Commercial 2 1 0
50%
— 1
327 Eradivir Inc. Commercial 2 1 1
50%
— 1
328 Esbjerg Og Grindsted Sygehus Commercial 2 0 0
0%
1 1
329 Escient Pharmaceuticals Inc. Commercial 2 1 1
50%
1 —
330 ETOP IBCSG Partners Foundation Academic 2 1 1
50%
— 1
331 European Organisation For Research And Treatment Of Cancer Commercial 2 2 2
100%
— —
332 Eva Pharma For Pharmaceuticals And Medical Appliances SAE Commercial 2 0 0
0%
2 —
333 Finnish Institute For Health And Welfare Academic 2 0 0
0%
— 2
334 Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Commercial 2 0 0
0%
1 1
335 Fondazione Italiana Linfomi Ets Commercial 2 0 0
0%
— 2
336 Friedrich-Schiller-Universitaet Jena Commercial 2 0 0
0%
2 1
337 Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIB… Academic 2 1 1
50%
— 1
338 Fundacio Institut De Recerca De L'Hospital De La Santa Creu … Academic 2 0 0
0%
1 1
339 Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infec… Commercial 2 0 0
0%
— 2
340 Fundacion GECP Commercial 2 1 1
50%
— 1
341 Fundacion PETHEMA Commercial 2 2 2
100%
— 1
342 Galecto Biotech AB Commercial 2 2 2
100%
— —
343 Gan & Lee Pharmaceuticals USA Corp. Commercial 2 0 0
0%
1 1
344 Gcp-Service International West GmbH Commercial 2 0 0
0%
— 2
345 Gebro Pharma GmbH Commercial 2 0 0
0%
1 1
346 Genenta Science S.p.A. Commercial 2 1 1
50%
— 1
347 Genetic S.p.A. Commercial 2 1 1
50%
— 1
348 Groupe Francophone Des Myelodysplasies Commercial 2 2 2
100%
— —
349 Groupement Des Hopitaux De L'Institut Catholique De Lille Academic 2 1 1
50%
— 1
350 Gruenenthal GmbH Commercial 2 1 1
50%
— 1
351 Grupo Espanol De Investigacion En Cancer De Ovario Commercial 2 1 1
50%
— 1
352 Haleon CH SARL Commercial 2 1 1
50%
1 —
353 Harmony Biosciences Management Inc. Commercial 2 1 1
50%
1 —
354 Heidelberg University Academic 2 0 0
0%
— 2
355 Helse Bergen HF Commercial 2 1 1
50%
— 1
356 Hospital Clinico San Carlos Academic 2 1 1
50%
— 1
357 Hvidovre Hospital Academic 2 2 2
100%
— —
358 Immunic AG Commercial 2 0 0
0%
— 2
359 Immutep Commercial 2 0 0
0%
— 2
360 Innovative Molecules GmbH Commercial 2 0 0
0%
2 —
361 Inozyme Pharma Inc. Commercial 2 0 0
0%
1 1
362 Institut fuer Klinische Krebsforschung IKF GmbH Academic 2 0 0
0%
— 2
363 Institut National De La Sante Et De La Recherche Medicale Academic 2 0 0
0%
— 2
364 Institut Paoli Calmettes Academic 2 0 0
0%
1 1
365 Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz Academic 2 1 1
50%
— 1
366 Instituto Oncologico Dr. Rosell S.L. Academic 2 0 0
0%
— 2
367 Integrative Research Laboratories Sweden AB Commercial 2 0 0
0%
2 —
368 Intellia Therapeutics Inc. Commercial 2 1 1
50%
1 —
369 Intergroupe Francophone De Cancerologie Thoracique Commercial 2 0 0
0%
— 2
370 Intra-Cellular Therapies Inc. Commercial 2 0 0
0%
— 2
371 Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRS… Commercial 2 0 0
0%
— 2
372 Itb-Med AB Commercial 2 1 1
50%
— 1
373 Janssen Vaccines & Prevention B.V. Commercial 2 1 1
50%
— 1
374 Jasper Therapeutics Inc. Commercial 2 0 0
0%
1 1
375 Kalvista Pharmaceuticals Limited Commercial 2 0 0
0%
— 2
376 Karolinska Institutet Academic 2 0 0
0%
1 1
377 Karuna Therapeutics Inc. Commercial 2 1 1
50%
— 1
378 Lakefront Biotherapeutics Commercial 2 0 0
0%
— 2
379 LAVA Therapeutics N.V. Commercial 2 1 1
50%
— 1
380 Leap Therapeutics Inc. Commercial 2 2 2
100%
— —
381 LiteVax B.V. Commercial 2 1 1
50%
1 —
382 LYSARC Commercial 2 1 1
50%
— 1
383 Mabxience Research S.L. Commercial 2 0 0
0%
1 1
384 Macrogenics Inc. Commercial 2 1 1
50%
— 1
385 Marinus Pharmaceuticals Inc. Commercial 2 1 1
50%
2 —
386 Mc2 Therapeutics Limited Commercial 2 2 2
100%
— —
387 Medibiofarma S.L. Commercial 2 3 3
150%
— —
388 Medical University Of Bialystok Academic 2 0 0
0%
— 2
389 Medizinische Hochschule Hannover Commercial 2 0 0
0%
— 3
390 Meiji Seika Pharma Co. Ltd. Commercial 2 2 2
100%
— —
391 Merz Therapeutics GmbH Commercial 2 2 2
100%
— —
392 Mundipharma Research Limited Commercial 2 2 2
100%
— 1
393 Mural Oncology Inc. Commercial 2 2 2
100%
— —
394 Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im … Commercial 2 0 0
0%
— 2
395 Nerviano Medical Sciences S.r.l. Commercial 2 2 2
100%
— 1
396 NMD Pharma A/S Commercial 2 0 0
0%
— 2
397 Nodthera Limited Commercial 2 1 1
50%
— 1
398 Nordsjaellands Hospital Academic 2 0 0
0%
2 —
399 Ntc S.r.l. Commercial 2 0 0
0%
1 1
400 Oculis Operations S.a.r.l. Commercial 2 0 0
0%
2 —
401 Oncoinvent ASA Commercial 2 0 0
0%
1 1
402 Opthea Limited Commercial 2 2 2
100%
— —
403 Orchard Therapeutics (Europe) Limited Commercial 2 1 1
50%
— 1
404 Osivax Commercial 2 0 0
0%
1 1
405 Ospedale Pediatrico Bambino Gesu Commercial 2 1 1
50%
— 1
406 Otsuka Pharmaceutical Development And Commercialization Inc. Commercial 2 0 0
0%
— 2
407 Pathalys Pharma Inc. Commercial 2 0 0
0%
2 —
408 Phaxiam Therapeutics Commercial 2 0 0
0%
2 —
409 Pirkanmaan hyvinvointialue Commercial 2 1 1
50%
— 1
410 PPM Services S.A. Commercial 2 0 0
0%
— 2
411 Principia Biopharma Inc. Commercial 2 0 0
0%
1 1
412 Prometheus Biosciences Inc. Commercial 2 2 2
100%
— —
413 Quince Therapeutics S.p.A. Commercial 2 2 2
100%
— —
414 Recode Therapeutics Inc. Commercial 2 0 0
0%
— 2
415 Recordati AG Commercial 2 1 1
50%
— 1
416 Repare Therapeutics USA Inc. Commercial 2 0 0
0%
2 —
417 Respirent Pharmaceuticals Co. Ltd. Commercial 2 0 0
0%
2 —
418 Rheinische Friedrich-Wilhelms-Universitaet Bonn Commercial 2 0 0
0%
— 2
419 River 2 Renal Corp. Commercial 2 1 1
50%
1 —
420 Ryvu Therapeutics S.A. Commercial 2 0 0
0%
— 2
421 Salix Pharmaceuticals Inc. Commercial 2 0 0
0%
1 1
422 Sanofi Pasteur Commercial 2 0 0
0%
— 2
423 Santhera Pharmaceuticals (Schweiz) AG Commercial 2 0 0
0%
3 —
424 Santiago Dexeus Font Fundacio Privada Commercial 2 0 0
0%
— 2
425 Shire Human Genetic Therapies Inc. Commercial 2 0 0
0%
— 2
426 Sint Maartenskliniek Stichting Commercial 2 1 1
50%
— 1
427 Sintetica S.A. Commercial 2 2 2
100%
— —
428 Sling Therapeutics Inc. Commercial 2 0 0
0%
1 1
429 SocraTec R&D Concepts in Drug Research and Development GmbH Commercial 2 0 0
0%
— 2
430 Spruce Biosciences Inc. Commercial 2 2 2
100%
— —
431 St Antonius Hospital Academic 2 0 0
0%
— 2
432 St. Olavs Hospital HF Academic 2 2 2
100%
— —
433 Stichting TRICALS Foundation Academic 2 1 1
50%
— 1
434 Substipharm Commercial 2 0 0
0%
2 —
435 Sumitomo Pharma Co. Ltd. Commercial 2 1 1
50%
— 1
436 Sydvestjysk Sygehus Commercial 2 0 1
0%
1 1
437 Tesaro Inc. Commercial 2 1 1
50%
— 1
438 Thoraxklinik Heidelberg gGmbH Academic 2 0 0
0%
— 2
439 Transcend Therapeutics Inc. Commercial 2 2 2
100%
— —
440 Transgene Commercial 2 0 0
0%
1 1
441 Trevena Inc. Commercial 2 2 2
100%
— —
442 Turku University Hospital Academic 2 0 0
0%
1 1
443 Ultragenyx Pharmaceutical Inc. Commercial 2 1 1
50%
1 —
444 United Therapeutics Corp. Commercial 2 1 1
50%
— 1
445 Universitaet Leipzig Commercial 2 1 1
50%
— 1
446 Universite Libre de Bruxelles Academic 2 1 1
50%
— 1
447 University College London Academic 2 1 1
50%
— 1
448 University Of Antwerp Academic 2 0 0
0%
1 1
449 University Of Oxford Academic 2 1 1
50%
— 1
450 Uniwersytet Jagiellonski Collegium Medicum Commercial 2 2 2
100%
— —
451 Uppsala Universitet Academic 2 0 0
0%
1 1
452 Upstream Bio Inc. Commercial 2 0 0
0%
— 2
453 UZ Brussel Commercial 2 0 0
0%
— 2
454 Vall D Hebron Institute Of Oncology Academic 2 1 1
50%
1 —
455 Varsinais-Suomen hyvinvointialue Commercial 2 0 0
0%
1 1
456 VectivBio AG Commercial 2 2 2
100%
— —
457 Ventus Therapeutics U.S. Inc. Commercial 2 0 0
0%
1 1
458 Verisfield Single Member S.A. Commercial 2 1 1
50%
1 —
459 Versantis AG Commercial 2 0 0
0%
— 2
460 Vestre Viken HF Commercial 2 0 0
0%
1 1
461 Vir Biotechnology Inc. Commercial 2 0 0
0%
1 1
462 Viracta Therapeutics Inc. Commercial 2 0 0
0%
4 —
463 Vivet Therapeutics Commercial 2 0 1
0%
2 —
464 Win Medica Pharmaceutical S.A. Commercial 2 1 1
50%
— 1
465 Xentria Inc. Commercial 2 0 0
0%
— 2
466 Zealand University Hospital Academic 2 2 2
100%
— —

Data notes & methodology